Literature DB >> 20024610

Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status.

Joan E Cunningham1, Alberto J Montero, Elizabeth Garrett-Mayer, Hans J Berkel, Bert Ely.   

Abstract

Breast cancer encompasses several distinct clinical entities of very different characteristics and behaviors, a fact which likely contributes to the higher breast cancer mortality in African-Americans (AA) despite the higher incidence in European-Americans (EA). We are interested in how incidence variability in cancer subtypes defined by combined estrogen receptor (ER) and grade contributes to racial mortality disparities. As an initial step, we compared age-specific and age-adjusted incidence rates for each ER/Grade subtype in South Carolina (SC-a southern state) with Ohio (a northern mid-western state), using state registry data for 1996-2004. Each ER/Grade subtype had a distinct incidence pattern and rate, with three striking racial/geographic differences. First, the racial incidence disparity in ER negative (ER-) cancers was mostly within the ER-/G3 subtype, of which AAs had ~65% higher incidence than did EAs; ER-/G2 was much less common, but of significantly higher incidence in AAs. Second, the racial disparity in ER positive (ER+) cancers was in the ER+/lower-grade cancers, with a marked EA excess in both states. Third, AA incidence of the ER+/lower-grade subtypes was ~26% higher in Ohio than in SC. The other subtypes (ER-/G1 and ER+/G3) varied minimally by race and state, and the latter showed a strong association with age. Age adjustment halved the racial difference in mean age at diagnosis to about 2 years younger in AAs, compared to 4 years younger in case comparisons. Use of age-adjusted and age-specific rates of breast cancer subtypes may improve understanding of racial incidence and mortality disparities over time and geography. This approach also may aid in estimating the race-specific incidence rates of triple-negative breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20024610     DOI: 10.1007/s10552-009-9472-2

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  27 in total

1.  Referrals among cancer services organizations serving underserved cancer patients in an urban area.

Authors:  Jenine K Harris; Julianne Cyr; Bobbi J Carothers; Nancy B Mueller; Victoria V Anwuri; Aimee I James
Journal:  Am J Public Health       Date:  2011-05-12       Impact factor: 9.308

Review 2.  Genetic susceptibility to breast cancer.

Authors:  Nasim Mavaddat; Antonis C Antoniou; Douglas F Easton; Montserrat Garcia-Closas
Journal:  Mol Oncol       Date:  2010-05-21       Impact factor: 6.603

3.  Mind the gap: racial differences in breast cancer incidence and biologic phenotype, but not stage, among low-income women participating in a government-funded screening program.

Authors:  Joan E Cunningham; Christine A Walters; Elizabeth G Hill; Marvella E Ford; Tiffany Barker-Elamin; Charles L Bennett
Journal:  Breast Cancer Res Treat       Date:  2012-12-13       Impact factor: 4.872

4.  Correlation of sonographic features of invasive ductal mammary carcinoma with age, tumor grade, and hormone-receptor status.

Authors:  Michael Aho; Abid Irshad; Susan J Ackerman; Madelene Lewis; Rebecca Leddy; Thomas L Pope; Amy S Campbell; Abbie Cluver; Bethany J Wolf; Joan E Cunningham
Journal:  J Clin Ultrasound       Date:  2012-09-20       Impact factor: 0.910

Review 5.  Ethnic differences in breast cancer survival: status and determinants.

Authors:  Gertraud Maskarinec; Cherisse Sen; Karin Koga; Shannon M Conroy
Journal:  Womens Health (Lond)       Date:  2011-11

6.  Clinicopathological features of triple-negative breast cancer in Taiwanese women.

Authors:  Kuo Yao-Lung; Chen Dar-Ren; Chang Tsai-Wang
Journal:  Int J Clin Oncol       Date:  2011-04-01       Impact factor: 3.402

Review 7.  Population and target considerations for triple-negative breast cancer clinical trials.

Authors:  Terry Hyslop; Yvonne Michael; Tiffany Avery; Hallgeir Rui
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

8.  Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium.

Authors:  Lynn Chollet-Hinton; Andrew F Olshan; Hazel B Nichols; Carey K Anders; Jennifer L Lund; Emma H Allott; Traci N Bethea; Chi-Chen Hong; Stephanie M Cohen; Thaer Khoury; Gary R Zirpoli; Virginia F Borges; Lynn A Rosenberg; Elisa V Bandera; Christine B Ambrosone; Julie R Palmer; Melissa A Troester
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-09-13       Impact factor: 4.254

9.  Genetic polymorphisms in RNA binding proteins contribute to breast cancer survival.

Authors:  Rohit Upadhyay; Sandhya Sanduja; Vimala Kaza; Dan A Dixon
Journal:  Int J Cancer       Date:  2012-09-18       Impact factor: 7.396

10.  Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.

Authors:  Delisha A Stewart; Jason H Winnike; Susan L McRitchie; Robert F Clark; Wimal W Pathmasiri; Susan J Sumner
Journal:  J Proteome Res       Date:  2016-08-03       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.